Table 4.
Renal Safety during Long-Term Tenofovir Disoproxil Fumarate Therapy
| Characteristics | 1 Year (n=426) | 2 Years (n=347) | 3 Years (n=236) | |
|---|---|---|---|---|
| Mean serum creatinine level changes, mg/dL | Total | 0.0±0.1 | −0.0±0.1 | −0.0±0.1 |
| Naïve | 0.0±0.1 | −0.0±0.1 | −0.0±0.1 | |
| Experienced | 0.0±0.1 | −0.0±0.1 | −0.0±0.1 | |
| p-value | 0.739 | 0.380 | 0.511 | |
| Mean eGFR changes, mL/min/1.73 m2 | Total | −1.7±11.1 | −0.4±10.0 | −1.5±10.3 |
| Naïve | −1.4±11.6 | −0.9±11.0 | −0.7±10.5 | |
| Experienced | −2.0±10.7 | −0.1±9.3 | −1.9±10.2 | |
| p-value | 0.621 | 0.508 | 0.401 | |
| Renal impairment | Total | 12/411 (2.9) | 6/342 (1.8) | 4/229 (1.7) |
| Naïve | 6/179 (3.4) | 2/132 (1.5) | 1/76 (1.3) | |
| Experienced | 6/232 (2.6) | 4/210 (1.9) | 3/153 (2.0) | |
| p-value | 0.872 | 1.000 | 1.000 | |
| Mean serum phosphorus level changes, mg/dL | Total | −0.0±0.6 | −0.0±0.6 | −0.1±0.5 |
| Naïve | −0.0±0.6 | −0.0±0.6 | −0.1±0.6 | |
| Experienced | −0.0±0.5 | −0.1±0.5 | −0.0±0.5 | |
| p-value | 0.633 | 0.729 | 0.492 | |
| Hypophosphatemia | Total | 0/359 (0.0) | 3/294 (1.0) | 1/191 (0.5) |
| Naïve | 0/169 (0.0) | 0/125 (0.0) | 1/72 (1.4) | |
| Experienced | 0/190 (0.0) | 3/169 (1.8) | 0/119 (0.0) | |
| p-value | - | 0.363 | 0.799 | |
Data are presented as mean±SD or number/number (%).
eGFR, estimated glomerular filtration rate.